30 closest matches · ranked by relevance
Cancer · Giant Cell Tumors · Giant Cell Tumor of Bone
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 260; 231; 12; 98 Participants
GCT · Giant Cell Tumor of Bone
Primary: Percentage of Participants With Giant Cell Tumor Response — 85.7 percentage of participants
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants
Tenosynovial Giant Cell Tumor · Pigmented Villonodular Synovitis (PVNS)
Primary: Number of Participants With Treatment-emergent Adverse Events — 7; 2 Participants
Giant Cell Tumor of Bone
Primary: Number of Participants Experiencing Adverse Events (AEs) of Interest (EOI) — 3; 0; 6; 1 Count of Participants
Pigmented Villonodular Synovitis · Giant Cell Tumors of the Tendon Sheath · Tenosynovial Giant Cell Tumor
Primary: Percentage of Participants With Symptomatic, Locally Advanced Tenosynovial Giant Cell Tumor (TGCT) Achieving Complete or Partial Response to Pexidartinib Compared With…
Bone Diseases
Primary: Resorption of Graft Material (GR) Compared at 24 Months — 51; 47 percentage of resorption — p=<0.01
Pigmented Villonodular Synovitis · Tenosynovial Giant Cell Tumor
Primary: The Incidence of Grade 3 and Grade 4 Adverse Events (AEs) and Defined as Dose-limiting Toxicities (DLTs) in Phase 1 — 0; 0; 0 Participants
Tenosynovial Giant Cell Tumor
Primary: Number of Treatment-Free Participants at 12 Months In The Treatment-free/Re-treatment Cohort — 8 Participants
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Tuberous Sclerosis · Subependymal Giant Cell Astrocytoma
Primary: Number With Observed Adverse Side Effects — 26; 25; 15; 14 participants
Osteoarthritis, Knee
Primary: Change From Baseline in the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Score at 1 Year — 23.3; 9.9 scores on a scale — p=<0.01
Giant Cell Arteritis
Primary: Number of Patients That Have Achieved Complete Remission of Disease — 17; 4 Participants — p=0.0301
Pigmented Villonodular Synovitis · Diffuse-type Giant Cell Tumor · Tenosynovial Giant Cell Tumor
Primary: Percentage of Participants With Progression Free Survival — 82 percentage of participants with PFS
Bone Cancer · Chondrosarcoma · Ewing's Sarcoma
Primary: T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects — 7.3; 7.7 milliseconds
Lymphedema · Musculoskeletal Complications · Radiation Fibrosis
Primary: Rate of Late Radiation Morbidity (≥ Grade 2 Lymphedema, Subcutaneous Fibrosis, or Joint Stiffness) at 2 Years From the Start of Radiotherapy as Measured by EORTC/RTOG…
Cleft Palate · Trauma
Primary: Bone Regeneration — 1.5; 3.3 implant sites
Tibial Fractures · Intra-Articular Fractures · Fracture Fixation, Internal
Primary: Resorption of Study Device — 4 Participants
Osteoarthritis
Primary: Allograft Stability — 0
Dermatofibrosarcoma Protuberans
Primary: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and…
Brain Tumors · Osteoporosis · Central Nervous System(CNS)Malignancies
Primary: Percent of Patients With Change in Combined Bone Mass Density T-score <= -0.5. — 3.7; 10.5 percentage of patients
Alveolar Bone Loss
Primary: Bone Regeneration — 79; 63 % bone height
Bone Metastases · Multiple Myeloma
Primary: Number of Responders — 54; 6 Participants
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Desmoid Fibromatosis
Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001
Giant Cell Arteritis
Primary: Number of CDU False-positive Patients — 73; 63; 0; 29 Participants
Sarcoma
Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants
Basal Cell Nevus Syndrome
Primary: Clinical Efficacy: Percent Change in Tumor Size of Treatment-targeted Surgically Eligible Basal Cell Carcinomas (SEBs) From Baseline — 51.29; 26.63; 21.82 percentage…
Alveolar Bone Loss · Periodontal Diseases
Primary: Number of Participants That Met the Success Criteria of Radiographic and Clinical Measurements — 16; 15; 19; 17 Participants